

## Data and Safety Monitoring Board statement regarding the continuation of REMED trial after interim analysis

After the review of the interim analysis, the DSMB has **not** detected reasons for stopping the recruitment of patients in the REMED trial.

Reasoning:

The decision of the DSMB is based on the interim analysis results of the primary outcome of ventilator-free days, on the acceptably high data quality and low drop-out rate. Further on, already published data on the comparison of different corticosteroid dosing regimens, the results of a pre-planned metaanalysis and the perceived need of the continuation of ongoing research in this matter were included in the decision-making process.

Yours sincerely

Prof. Petr Štourač  
Chair of DSMB

Dr. Milan Kratochvíl  
Administrator and Vice-chair of DSMB